Dihydrotestosterone acetate

Dihydrotestosterone acetate (DHTA) is a synthetic androgen and anabolic steroid and a derivative of dihydrotestosterone (DHT). It is more commonly known as androstanolone acetate and stanolone acetate.

Chemistry

Dihydrotestosterone acetate, like all synthetic androgens and anabolic steroids, is derived from testosterone. It is specifically a derivative of DHT, which is itself a metabolite of testosterone. DHTA is formed by the addition of an acetyl group to the 17th carbon position of DHT. This modification increases the hormone's anabolic activity and reduces its androgenic potency.

Pharmacology

DHTA acts as a potent androgen receptor agonist. It has a high affinity for the androgen receptor and is believed to have a role in the development and maintenance of male secondary sexual characteristics. DHTA is also thought to have anabolic effects, promoting the growth and repair of muscle tissue.

Medical Uses

DHTA has been used in the treatment of conditions such as hypogonadism, a condition in which the body does not produce enough testosterone. It has also been used to treat certain forms of breast cancer in women. However, its use in these contexts is limited due to its potential for causing virilization (the development of male characteristics) in women and children.

Side Effects

The side effects of DHTA are similar to those of other androgens and anabolic steroids. These can include acne, hair loss, increased body hair growth, and changes in mood and behavior. More serious side effects can include liver damage, cardiovascular disease, and an increased risk of prostate cancer in men.

Legal Status

In many countries, including the United States, DHTA is classified as a controlled substance. This means that its use, possession, and distribution are regulated by law. In the U.S., it is classified as a Schedule III controlled substance under the Controlled Substances Act.

See Also

• Anabolic steroid
• Androgen
• Testosterone
• Dihydrotestosterone